The Anti-Diabetes Drugs market in Bahrain has been steadily growing in recent years.
Customer preferences: Bahrain has a high prevalence of diabetes, with approximately 15% of the population affected by the disease. As a result, there is a high demand for anti-diabetes drugs in the country. Patients in Bahrain are increasingly seeking out more effective and convenient treatment options that can help them manage their condition and improve their quality of life.
Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Bahrain is the growing popularity of newer, more advanced drugs that offer better efficacy and fewer side effects. In particular, there has been a significant increase in the use of GLP-1 receptor agonists and SGLT2 inhibitors, which are both relatively new classes of drugs that have been shown to be highly effective in managing diabetes.Another trend in the market is the increasing use of combination therapies, which involve the use of multiple drugs to treat diabetes. Combination therapies are becoming more popular in Bahrain as they offer a more comprehensive approach to diabetes management, and can help patients achieve better glycemic control.
Local special circumstances: The Bahraini government has implemented a number of initiatives aimed at improving diabetes care in the country, including the establishment of specialized diabetes clinics and the provision of free diabetes medication to patients. These initiatives have helped to raise awareness of diabetes and improve access to treatment for patients.
Underlying macroeconomic factors: Bahrain has a relatively high GDP per capita compared to other countries in the region, which has helped to drive demand for anti-diabetes drugs. However, the country is also facing significant economic challenges, including high levels of public debt and a reliance on oil exports. As a result, there is a growing need for cost-effective diabetes treatments that can help to manage the disease without placing a significant burden on the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
